TPM3 and cancer: In 2014, when we started the syntheses of imidazo[1,2-b]pyridazine-based radioligands, it was demonstrated that NTRK fusion were actionable drivers in human cancers, however only a few non selective Trk inhibitors had been used in a therapeutic approach.